Literature DB >> 12954112

Effects of base modifications on antisense properties of 2'-O-methoxyethyl and PNA oligonucleotides.

Peter Sazani1, Anna Astriab-Fischer, Ryszard Kole.   

Abstract

A recently developed antisense splicing assay was used to determine the relative activities of 2'-O-methoxyethoxy (2'-MOE) phosphorothioate oligonucleotides containing base modifications. In the assay, RNase H-inactive oligonucleotides are used to block aberrant splicing and restore correct splicing of an Enhanced Green Fluorescence Protein (EGFP) reporter pre-mRNA stably expressed in HeLa cells. Thus, the extent of EGFP upregulation is proportional to the antisense activity of the tested molecule. The base modifications included C-5 propynyl analogs of uridine and cytidine and phenoxazine and G-clamp analogs of cytosine. Base-modified 2'-MOE oligonucleotides were delivered to the HeLa EGFP-654 test cells by cationic lipid transfection or scrape-loading or without any delivery method (free uptake). When delivered with a cationic lipid, the G-clamp and phenoxazine oligomers showed increases in activity over the unmodified 2'-MOE parent compound. However, when delivered by scrape-loading or without a delivery method, the unmodified oligomer performed best. The results suggest that base modifications do not enhance the free uptake activity of RNase H inactive 2'-MOE oligomers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954112     DOI: 10.1089/108729003768247583

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  6 in total

Review 1.  DNA and RNA derivatives to optimize distribution and delivery.

Authors:  Eric Wickstrom
Journal:  Adv Drug Deliv Rev       Date:  2015-04-22       Impact factor: 15.470

2.  Enhanced delivery of peptide-morpholino oligonucleotides with a small molecule to correct splicing defects in the lung.

Authors:  Yan Dang; Catharina van Heusden; Veronica Nickerson; Felicity Chung; Yang Wang; Nancy L Quinney; Martina Gentzsch; Scott H Randell; Hong M Moulton; Ryszard Kole; Aiguo Ni; Rudolph L Juliano; Silvia M Kreda
Journal:  Nucleic Acids Res       Date:  2021-06-21       Impact factor: 16.971

3.  Anti-tumor activity of splice-switching oligonucleotides.

Authors:  John A Bauman; Shyh-Dar Li; Angela Yang; Leaf Huang; Ryszard Kole
Journal:  Nucleic Acids Res       Date:  2010-08-18       Impact factor: 16.971

4.  Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents.

Authors:  Steve D Wilton; Sue Fletcher
Journal:  Appl Clin Genet       Date:  2011-03-10

5.  Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides.

Authors:  Andrew D Burdick; Simone Sciabola; Srinivasa R Mantena; Brett D Hollingshead; Robert Stanton; James A Warneke; Ming Zeng; Elena Martsen; Alexander Medvedev; Sergei S Makarov; Lori A Reed; John W Davis; Laurence O Whiteley
Journal:  Nucleic Acids Res       Date:  2014-02-18       Impact factor: 16.971

6.  Restoration of correct splicing in IVSI-110 mutation of β-globin gene with antisense oligonucleotides: implications and applications in functional assay development.

Authors:  Sima Mansoori Derakhshan; Mahmoud Shekari Khaniani
Journal:  Iran J Basic Med Sci       Date:  2017-06       Impact factor: 2.699

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.